Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3K inhibitor, linperlisib Linperlisib provides... 01/04/2021 | 未分类 | 0 comments | Read More
Shanghai Yingli Pharmaceutical Co., Ltd. initiates phase I clinical trial of YL-90148, a selective uric acid reabsorption inhibitor for the treatment of gout and asymptomatic hyperuricemia Nov. 19, 2018, Shang... 19/11/2018 | News | Read More
The phase I clinical trial protocol discussion meeting for Shanghai Yingli Pharmaceutical’s novel immune-oncology agent YL-13027 has been successfully held in Shanghai Nov. 14, 2018, Shang... 14/11/2018 | News | Read More
The phase II clinical trial investigators meeting for Shanghai Yingli Pharmaceutical’s novel anti-cancer agent YY-20394 has been successfully held in Chengdu Oct. 26, 2018, Shang... 26/10/2018 | News | Read More
Shanghai Yingli Pharmaceutical announces FDA Orphan Drug Designation for YY-20394 for both indications (FL and CLL/SLL) Oct. 11, 2018, Shang... 11/10/2018 | News | Read More
